Rovi stock: Barron's cites EUR 75.85 average target for Rovi stock

Published on 10/21/2026 at 15:01 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Rovi results are due November 5, 2026. Rovi stock costs EUR 58.75 on October 21, 2026, plus 0.09 percent versus its BME prior close.

Target and reporting date

Barron's cited a EUR 75.85 average target from 11 ratings on October 20, 2026.
Rovi will publish first nine months 2026 results on November 5, 2026.
Rovi stock costs EUR 58.75 at Lang & Schwarz on October 21, 2026, plus 0.09 percent versus the BME prior close.

Rovi, ES0157261019, Illustration mit AI erstellt.

Laboratorios Farmaceuticos Rovi stock has an average target of EUR 75.85 from 11 ratings, according to Barron's on October 20, 2026. That target stands 29.11 percent above the EUR 58.75 Lang & Schwarz price. Rovi will publish first nine months 2026 financial results on November 5, 2026, according to the Rovi investor calendar. At Lang & Schwarz, the stock was trading at EUR 58.75 on October 21, 2026 at 2:53 p.m. CEST, plus 0.09 percent versus the BME prior close of EUR 58.70.

Results date sets the next marker

The November 5 publication will cover the first nine months of 2026, giving investors the next reported checkpoint after Rovi's first-half figures. The company reported total revenue of EUR 357.0 million for the first half of 2026, up 13.00 percent from the first half of 2025. Operating revenue reached EUR 344.2 million, an increase of 9.00 percent, while contract development and manufacturing revenue grew 38.00 percent during the period, according to the Rovi investor calendar.

Rovi remains below its yearly high

The stock's 52-week range was EUR 53.10 to EUR 86.70 as of October 20, 2026. At EUR 58.75, Rovi stood 32.24 percent below the high and 10.63 percent above the low. The same market page listed a year-to-date decline of 7.56 percent and volume of 59,530 shares for October 20, 2026.

Valuation meets the November date

Rovi had a trailing price-to-earnings ratio of 16.21 and a dividend yield of 1.32 percent on October 20, 2026. Its market value was EUR 3.0 billion on October 21, 2026. The scheduled results date therefore offers the next concrete test for the revenue growth reported in the first half.

Comparison with peers

Rovi: plus 0.09 percent, price-to-earnings ratio 16.21, market capitalization EUR 3.0 billion, BME and EUR, October 21, 2026.

Almirall: minus 0.58 percent, price-to-earnings ratio 31.03, market capitalization EUR 2.2 billion, BME and EUR, October 21, 2026.

Grifols: minus 1.70 percent, price-to-earnings ratio 14.90, market capitalization EUR 6.1 billion, BME and EUR, October 21, 2026.

Target remains the key valuation marker

The EUR 75.85 average target sits materially above the Lang & Schwarz quote, while Rovi's next results date is already set. The company enters that reporting point with first-half total revenue of EUR 357.0 million and operating revenue growth of 9.00 percent.

The stock was trading at EUR 58.75 at Lang & Schwarz on October 21, 2026 at 2:53 p.m. CEST, plus 0.09 percent versus the BME prior close of EUR 58.70.

The further course of trading is shown by the continuously updated real-time quote of Rovi stock.